Achievements in Multi-specific Antibody and ADC Platform Development Unveiled at the Largest Cancer Conference in the US
Celltrion and Celltrion Pharm announced on April 22 that they will both participate in the world's largest cancer conference, AACR (American Association for Cancer Research) 2025, which will be held in Chicago, USA, from April 25 to 30.
Celltrion is set to present preclinical results for its multi-specific antibody new drug CT-P72 for the first time, while Celltrion Pharm will unveil its achievements in developing a dual-payload antibody-drug conjugate (ADC) for the first time. As both companies showcase next-generation modalities and platform technologies in the antibody field on the international stage for the first time, interest from related experts and investors is growing.
First, Celltrion will deliver an oral presentation of the preclinical results for CT-P72, which is being co-developed with the US biotech company ABPRO, on April 27 (local time). CT-P72 is a multi-specific antibody-based HER2 (human epidermal growth factor receptor 2) targeted T-cell engager (TCE) that induces the destruction of cancer cells by linking HER2-positive cancer cells with immune T cells. Since CT-P72 is a multi-specific antibody new drug that is distinct from the ADC new drug pipeline previously disclosed by Celltrion at events such as World ADC, there is expected to be significant interest in the detailed data and direction of development.
Celltrion Pharm will present CTPH-02 in a poster session on April 30 (local time). CTPH-02 is a dual-payload ADC platform technology that combines payloads (cytotoxic anticancer agents) with different mechanisms of action. As two types of payloads are combined, it is expected that when fused with antibodies, the platform will demonstrate strong efficacy and high therapeutic precision.
In particular, Celltrion will present its new drug pipeline, while Celltrion Pharm will announce its achievements in developing platform technologies for next-generation therapeutics. This is expected to create synergy in research and development (R&D) in the future.
Celltrion aims to submit investigational new drug (IND) applications for a total of 13 candidates?including 9 in the ADC field and 4 in the multi-specific antibody field?to major global institutions by 2028. Building on its accumulated know-how in the antibody sector, including the development of the world's first antibody biosimilar, and bold investments, the company plans to rapidly expand its new drug portfolio and solidify its position as a leader in antibody-based new drugs.
A Celltrion Group representative stated, "Our major affiliates will continue to secure outstanding new drug candidates and platform technologies based on their excellent R&D capabilities and execution, further strengthening our global competitiveness. By advancing next-generation therapeutics, we will lay the foundation for sustainable future growth and strive to become a 'global big pharma' company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
